NF

Naomi Fried

CEO & Founder PharmStars; Managing Partner & Co-founder, Ambit Health Ventures

Greater Boston

Invests in

Stages:

  • Min Investment:

    $100,000.00
  • Max Investment:

    $5,000,000.00
  • Target Investment:

    $1,500,000.00

Work Experience

  • Member of the Board of Advisors

    2024

    Panacea-ml revolutionizes clinical trial design with its data-driven, explainable-AI SaaS platform. Its cutting-edge AI technology addresses the primary causes of clinical development failure by identifying patient profiles that maximize therapeutic efficacy, minimize safety risks, and improve participant retention. Leveraging historical clinical trials and over 1 million real-world patient health records, Panacea-ml's AI model enhances patient selection criteria, reduces cohort sizes, and uncovers novel marker-endpoint interrelations, surrogate markers, and causal relationships beyond simple statistical correlations.

  • Founder and CEO

    2021

  • Managing Partner and Co-Founder

    2020

    Investing in early-stage "must-have" digital health innovations

  • Board Member

    2022

    Head Diagnostics is developing innovative technology and an associated handheld medical device for the diagnosis of concussion (mTBI) and Parkinson’s Disease (PD). This novel technology will provide for rapid assessment and assist clinicians in making objective diagnoses of brain disease and brain impairment.

2022

  • Advisory Board Member

    2022

  • Member Board Of Directors

    2021

2019 - 2022

  • Industry Advisory Board Member

    2019 - 2022

    Industry Advisory Board Member of this leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease until acquisition by Pfizer. ResApp’s machine learning algorithms use sound to diagnose and measure the severity of respiratory conditions without the need for additional hardware. Clinical studies at leading hospitals have demonstrated accurate diagnosis of pneumonia, asthma/reactive airway disease, bronchiolitis, croup, chronic obstructive pulmonary disease and upper respiratory tract infections. ResApp has also obtained excellent results for screening of obstructive sleep apnea in a double-blind, prospective clinical study.

2017 - 2020

  • Advisory Board Member

    2017 - 2020

    Advisory board member to this leading digital health start-up that diagnoses neurodegenerative diseases non-invasively using a proprietary algorithms for analyzing typing patterns.

  • Founder and CEO

    2016 - 2020

    Providing digital health strategy and innovation infrastructure management consulting services to a range of healthcare clients including, pharma, providers and start-ups. Recent Consulting Engagement: ♦ Roche Pharmaceuticals: Advising on digital healthcare and digital-knowledge management strategy. Creating strategic frameworks for building competencies and capabilities for a robust digital health program. Advising client on potential innovative digital health pilot projects to address unmet needs in various therapeutic areas. ♦Children's Hospital of Los Angeles: Development of a strategic plan for a robust, enterprise innovation program. Providing strategic guidance on program vision, goals, programs, structure, organization, staffing, and budgets. ♦Merck, Roche and others: Advice on emerging trends in healthcare innovation and digital health in the pharmaceutical industry.

2014 - 2015

  • Vice President, Medical Information, Innovation and External Partnerships

    2014 - 2015

    Led five functions catalyzing innovation to support patients, healthcare professionals, and partners. • Developed strategy and led the “Innovation Beyond the Molecule” program to deliver non-pharmacological value to patients and providers. - Launched the “Patient Center” to respond to inquiries about access to pipeline compounds. - Identified, evaluated, and pursued licensing of novel digital health solutions to assist MS patients manage depression and fatigue. Built financial model and engaged internal stakeholders in concept. - Conceived of novel mechanism to leverage tele-health for patient medication adherence in clinical trials. • Managed Medical Information group that responds to all product inquiries. Oversaw development of globalization strategy for managing medical information needs across many countries and languages, with goals to reduce redundancies and improve compliance and communication • Oversaw Scientific Meetings group responsible for executing non-commercial presence at scientific meetings. Directed the creation of cross-functional (medical, commercial, global, regional, public relations, etc.) “Congress Governance” team to set high-level strategy and policies • Led two teams: the External Partnership group responsible for engagement with clinical thought leaders and the Medical Education group that supports continuing, physician medical education.